Research Center for Macromolecules and Biomaterials, National Institute for Materials Science (NIMS), 1-1 Namiki, Tsukuba, Ibaraki 305-0044, Japan.
Research Center for Macromolecules and Biomaterials, National Institute for Materials Science (NIMS), 1-1 Namiki, Tsukuba, Ibaraki 305-0044, Japan; Biotechnology and Life Sciences Department, Faculty of Postgraduate Studies for Advanced Sciences (PSAS), Beni-Suef University, Beni-Suef 62511, Egypt.
J Control Release. 2023 Nov;363:550-561. doi: 10.1016/j.jconrel.2023.10.010. Epub 2023 Oct 9.
Anticancer drug resistance invariably emerges and poses a significant barrier to curative therapy for various breast cancers. This results in a lack of satisfactory therapeutic medicine for cancer treatment. Herein, a universal vector system for drug-resistance breast cancer was designed to meet the needs of reversed multidrug resistance, thermo-chemotherapy, and long-term drug release behavior. The vector system comprises polycaprolactone (PCL) nanofiber mesh and magnetic nanoparticles (MNPs). PCL has excellent biocompatibility and electrospinning performance. In this study, MNPs were tailored to be thermogenic in response to an alternating magnetic field (AMF). PCL nanofiber can deliver various chemotherapy drugs, and suitable MNPs encapsulated in the nanofiber can generate hyperthermia and synergistic effect with those chemotherapy drugs. Therefore, a more personalized treatment system can be developed for different breast malignancies. In addition, the PCL nanofiber mesh (NFM) enables sustained release of the drugs for up two months, avoiding the burden on patients caused by repeated administration. Through model drugs doxorubicin (DOX) and chemosensitizers curcumin (CUR), we systematically verified the therapeutic effect of DOX-resistance breast cancer and inhibition of tumor generation in vivo. These findings represent a multifaceted platform of importance for validating strategic reversed MDR in pursuit of promoted thermo-chemotherapeutic outcomes. More importantly, the low cost and excellent safety and efficacy of this nanofiber mesh demonstrate that this can be customized multi-function vector system may be a promising candidate for refractory cancer therapy in clinical.
抗癌药物耐药性不可避免地出现,对各种乳腺癌的治愈治疗构成重大障碍。这导致缺乏令人满意的癌症治疗治疗药物。本文设计了一种通用的耐药性乳腺癌载体系统,以满足逆转多药耐药性、热化疗和长期药物释放行为的需求。该载体系统包括聚己内酯(PCL)纳米纤维网和磁性纳米颗粒(MNPs)。PCL 具有出色的生物相容性和电纺性能。在这项研究中,MNPs 被定制为对交变磁场(AMF)产生热效应。PCL 纳米纤维可以输送各种化疗药物,并且合适的 MNPs 封装在纳米纤维中可以产生热疗并与这些化疗药物产生协同作用。因此,可以为不同的乳腺癌恶性肿瘤开发更个性化的治疗系统。此外,PCL 纳米纤维网(NFM)可实现药物的持续释放长达两个月,避免了因重复给药给患者带来的负担。通过模型药物阿霉素(DOX)和化疗增敏剂姜黄素(CUR),我们系统地验证了 DOX 耐药性乳腺癌的治疗效果和体内肿瘤生成的抑制作用。这些发现代表了一个重要的多方面平台,用于验证追求促进热化疗效果的战略逆转 MDR。更重要的是,这种纳米纤维网的低成本、出色的安全性和有效性表明,这种定制多功能载体系统可能是临床难治性癌症治疗的有前途的候选者。